Literature DB >> 6322974

Schizophyllan (SPG)-treated macrophages and anti-tumor activities against syngeneic and allogeneic tumor cells. I. Characteristics of SPG-treated macrophages.

I Sugawara, K C Lee, M Wong.   

Abstract

We tested anti-tumor activities of macrophages treated with a neutral polysaccharide, schizophyllan (SPG), against syngeneic and allogeneic tumor cell lines. SPG was a macrophage stimulant which was not mitogenic to lymphocytes. That made a sharp contrast with the data that Corynebacterium parvum, BCG, and muramyl dipeptide (MDF) were macrophage stimulants which had lymphocyte-activating properties. Treatment of SPG-treated PEC with Thy12 monoclonal antibody and guinea pig complement did not affect the capabilities of tumor-cell-growth suppression by the treated PEC. Thus, the effector cells were peritoneal adherent cells (macrophages morphologically) and effector-to-target contact seemed to be necessary for effective tumor-cell-growth inhibition, although contradictory data exist for this. Murine peritoneal adherent cells harvested 4 days after a single IP injection of SPG at a dose of 100 mg/kg body weight of mouse showed the most prominent cytostatic and cytotoxic activities against syngeneic and allogeneic tumor cells. The distribution of anti-tumor activity in macrophages of various sizes followed the same pattern as macrophages treated with C. Parvum, i.e., larger macrophages showed more remarkable anti-tumor activity. Crude nonadherent peritoneal cells incubated with SPG at a concentration of 10 micrograms/ml, 100 micrograms/ml, or 1 mg/ml did not secrete lymphokine that rendered macrophages cytotoxic, while ConA-treated nonadherent cells did so. Furthermore, spleen cells treated with SPG in vivo did not secrete macrophage-activating lymphokine in the presence of SPG. On the other hand, addition of 1 mg/ml of SPG-treated peritoneal adherent cells and bone-marrow-derived macrophages in vitro rendered them cytotoxic to a moderate degree. This implies that SPG may activate macrophages directly, allowing them to become cytotoxic in the peritoneal cavity. Lastly, SPG could induce production of II-1-like factor to a moderate degree. SPG, whose molecular structure is well elucidated, will provide us with a strong tool to analyze the mechanism of macrophage activation both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322974     DOI: 10.1007/bf00205419

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  23 in total

1.  Lymphocyte-mediated modification of blood-derived macrophage function in vitro; inhibition of growth of intracellular mycobacteria with lymphokines.

Authors:  T Godal; R J Rees; J O Lamvik
Journal:  Clin Exp Immunol       Date:  1971-04       Impact factor: 4.330

2.  Endotoxin and double stranded RNA render macrophages cytotoxic.

Authors:  P Alexander; R Evans
Journal:  Nat New Biol       Date:  1971-07-21

3.  Characterization of macrophage subpopulations responsive to activation by endotoxin and lymphokines.

Authors:  K C Lee; M Wong; D McIntyre
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

4.  Carrageenans, highly sulfated polysaccharides and macrophage-toxic agents: newly found human T lymphocyte mitogens.

Authors:  I Sugawara; S Ishizaka; G Möller
Journal:  Immunobiology       Date:  1982-12       Impact factor: 3.144

5.  Mitogenic activity of the cell walls of mycobacteria, nocardia, corynebacteria and anaerobic coryneforms.

Authors:  I Azuma; T Taniyama; K Sugimura; A Aladin; Y Yamamura
Journal:  Jpn J Microbiol       Date:  1976-08

6.  Inhibition of pulmonary metastasis of Lewis lung carcinoma by a glucan, Schizophyllan.

Authors:  T Yamamoto; T Yamashita; E Tsubura
Journal:  Invasion Metastasis       Date:  1981

7.  Spectrum and possible mechanism of carrageenan cytotoxicity.

Authors:  P J Catanzaro; H J Schwartz; R C Graham
Journal:  Am J Pathol       Date:  1971-08       Impact factor: 4.307

8.  Mechanisms of target recognition and destruction in macrophage-mediated tumor cytotoxicity.

Authors:  D O Adams; W J Johnson; P A Marino
Journal:  Fed Proc       Date:  1982-04

9.  Cooperative role of T lymphocytes and macrophages in anti-tumor activity of mice pretreated with schizophyllan (SPG).

Authors:  M Suzuki; T Arika; K Amemiya; M Fujiwara
Journal:  Jpn J Exp Med       Date:  1982-04

10.  Macrophage stimulation by bacterial lipopolysaccharides. I. Cytolytic effect on tumor target cells.

Authors:  W F Doe; P M Henson
Journal:  J Exp Med       Date:  1978-08-01       Impact factor: 14.307

View more
  9 in total

1.  Immunoregulatory effects of sizofiran (SPG) on lymphocytes and polymorphonuclear leukocytes.

Authors:  K Yoneda; E Ueta; T Yamamoto; T Osaki
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

2.  Update on the immunomodulating activities of glucans.

Authors:  N R Di Luzio
Journal:  Springer Semin Immunopathol       Date:  1985

3.  Immune reaction induced by X-rays and pions and its stimulation by schizophyllan (SPG).

Authors:  T Inomata; G B Goodman; C J Fryer; D J Chaplin; B Palcic; G K Lam; A Nishioka; Y Ogawa
Journal:  Br J Cancer Suppl       Date:  1996-07

4.  Effect of a glucan, sizofiran, on natural-killer activity of 5-fluorouracil-treated murine bone marrow cells.

Authors:  Y Tsuchiya; M Matsutani; M Inoue; S Sato; T Asano; M Yajima
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

5.  Analysis of effector T cells against the murine syngeneic tumor MethA in mice orally administered antitumor polysaccharide SPR-901.

Authors:  Y Takeda; M Tanaka; H Miyazaki; S Takeo; K Nomoto; Y Yoshikai
Journal:  Cancer Immunol Immunother       Date:  1994-03       Impact factor: 6.968

6.  Generation of Recombinant Antibodies against the beta-(1,6)-Branched beta-(1,3)-D-Glucan Schizophyllan from Immunized Mice via Phage Display.

Authors:  Jörn Josewski; Sabine Buchmeier; André Frenzel; Philip Tinnefeld; Stefan Dübel; Udo Rau
Journal:  Biotechnol Res Int       Date:  2017-05-23

7.  Schizophyllum commune induces IL-17-mediated neutrophilic airway inflammation in OVA-induced asthma model mice.

Authors:  Jun Hanashiro; Yasunori Muraosa; Takahito Toyotome; Koichi Hirose; Akira Watanabe; Katsuhiko Kamei
Journal:  Sci Rep       Date:  2019-12-18       Impact factor: 4.379

8.  Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells.

Authors:  Yuji Kitahata; Tomohiro Kanuma; Masayuki Hayashi; Nobuyoshi Kobayashi; Koji Ozasa; Takato Kusakabe; Burcu Temizoz; Etsushi Kuroda; Hiroki Yamaue; Cevayir Coban; Takuya Yamamoto; Kouji Kobiyama; Taiki Aoshi; Ken J Ishii
Journal:  Oncotarget       Date:  2016-08-02

9.  Structural insights into antigen recognition of an anti-β-(1,6)-β-(1,3)-D-glucan antibody.

Authors:  Kwang Hoon Sung; Jörn Josewski; Stefan Dübel; Wulf Blankenfeldt; Udo Rau
Journal:  Sci Rep       Date:  2018-09-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.